Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382359 | 0.94 | CYP2D6 (0.48) | BCHECYP2D6CYP2C19CHRM3 | |
| SCHEMBL19903722 | 0.80 | CYP2D6 (0.46) | BCHECYP2D6CYP2C19CHRM3 | |
| SCHEMBL2895068 | 0.80 | CYP2D6 (0.43) | CYP2D6CYP2C19CHRM3 | |
| SCHEMBL24261571 | 0.79 | GNAO1 (0.51) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL26511527 | 0.79 | GNAO1 (0.51) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL27364662 | 0.78 | GNAO1 (0.50) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL12911942 | 0.77 | GNAO1 (0.49) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL10442916 | 0.77 | GNAI3 (0.54) | BCHEGNAI3GNAO1GNAI1CHRM3 | |
| Acetic Acid SCHEMBL23004388 | 0.75 | BCHE (0.52) | BCHEGNAI3GNAO1GNAI1 | |
| Acetic Acid SCHEMBL23004547 | 0.75 | BCHE (0.52) | BCHEGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049678-A2 | TREATMENT OF ENERGY UTILIZATION DISEASES | SUMMIT CORPORATION PLC (GB) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010015815-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2010-02-11 | — | — | WO | disclosed |